admin – Page 7521 – Get News Story

Controversal ‘The Naked Truth Tarot’ Deck, Featuring Nude Classical Art, Triumphs on Kickstarter

Wyoming, WY – In an unparalleled show of support, Mustapha’s Kickstarter project, The Naked Truth Tarot, has far exceeded its initial goal of $5,000, raising over $37,000. This isn’t just another tarot deck; it’s a bold statement. By integrating nude classical paintings into each card, Mustapha’s project invites backers to explore the human form in its most authentic, unadulterated beauty.

“From the start, we knew this deck was special,” Mustapha reflects. “It’s about connecting with the raw, unfiltered essence of humanity. These paintings aren’t just art; they’re a conversation about beauty, identity, and the power of seeing and accepting ourselves and each other.”

Born out of Mustapha’s passion for classical art and a desire to bring a fresh, unapologetically honest perspective to tarot, The Naked Truth Tarot is as much an artistic endeavor as it is a spiritual one. Each card challenges the viewer, encouraging a deeper understanding and appreciation of the human body’s diversity and beauty.

As the campaign continues to gain momentum, backers are offered a range of rewards, from exclusive decks featuring these beautifully rendered paintings to unique art pieces and more. Mustapha and his team are already looking towards stretch goals that promise to enhance the deck further, ensuring that The Naked Truth Tarot leaves a lasting impression on all who encounter it.

For more details or to support The Naked Truth Tarot, visit their Kickstarter page or reach out to Mustapha directly at contact@baroquetarot.com

Media Contact
Company Name: Spectrum Projects LLC
Contact Person: Mustapha
Email: Send Email
Country: United States
Website: www.baroquetarot.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Controversal \’The Naked Truth Tarot\’ Deck, Featuring Nude Classical Art, Triumphs on Kickstarter

Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

DelveInsight’s, “Extensive Stage Small Cell Lung Cancer Pipeline Insight 2024” report provides comprehensive insights about 40+ Extensive Stage Small Cell Lung Cancer companies and 40+ pipeline drugs in the Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline landscape. It covers the Extensive Stage Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Extensive Stage Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Extensive Stage Small Cell Lung Cancer Pipeline Report

DelveInsight’s Extensive Stage Small Cell Lung Cancer pipeline report depicts a robust space with 40+ Extensive Stage Small Cell Lung Cancer companies working to develop 40+ pipeline therapies for Extensive Stage Small Cell Lung Cancer treatment.
The leading Extensive Stage Small Cell Lung Cancer Companies working in the market includes Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., aizhou HoudeAoke Biomedical Co., Ltd., Celgene, MedImmune, Xcovery Holding Company LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, and others.
Promising Extensive Stages Small Cell Lung Cancer Pipeline Therapies in the various stages of development includes Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.
December 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Atezolizumab, Lurbinectedin, Carboplatin and Etoposide. The study consists of 2 phases: an induction phase and a maintenance phase. Participants need to have an ongoing response or stable disease per the Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria after completion of 4 cycles of carboplatin, etoposide, and atezolizumab treatment in order to be considered for eligibility screening for the maintenance phase. Eligible participants will be randomized in a 1:1 ratio to receive either lurbinectedin plus atezolizumab or atezolizumab in the maintenance phase.
December 2023: Shanghai Henlius Biotech announced a study of Phase 3 clinical trials for Serplulimab + chemotherapy (carboplatin-etoposide) and Atezolizumab + chemotherapy (carboplatin-etoposide). A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE).
December 2023: Amgen announced a study of Phase 1 clinical trials for Tarlatamab, Carboplatin, Etoposide, Durvalumab and Atezolizumab. This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Request a sample and discover the recent advances in Extensive Stage Small Cell Lung Cancer Treatment Drugs @ Extensive Stage Small Cell Lung Cancer Pipeline Outlook Report

The Extensive Stage Small Cell Lung Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Extensive Stage Small Cell Lung Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Extensive Stage Small Cell Lung Cancer clinical trial landscape.

Extensive Stage Small Cell Lung Cancer Overview

Extensive Stage Small Cell Lung Cancer (ESCLC) (ESCLC) is in the stage where it has spread to other parts of the body, such as the other lung or the brain. Without treatment, the average life expectancy for a person with an extensive-stage small cell lung cancer diagnosis is two to four months.

Find out more about Extensive Stage Small Cell Lung Cancer Treatment Landscape @ Drugs for Extensive Stage Small Cell Lung Cancer Treatment

Extensive Stage Small Cell Lung Cancer Emerging Drugs Profile

LY 2510924: Eli Lilly and Company
Tiragolumab: Genentech

Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 40+ key Extensive Stage Small Cell Lung Cancer companies which are developing the Extensive Stage Small Cell Lung Cancer therapies. The Extensive Stage Small Cell Lung Cancer companies which have their Extensive Stage Small Cell Lung Cancer (ESCLC) drug candidates in the most advanced stage, i.e. phase III include, Genentech.

DelveInsight’s Extensive Stage Small Cell Lung Cancer Pipeline Report covers around 40+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Extensive Stage Small Cell Lung Cancer (ESCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravitreal
Subretinal
Topical.
Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Learn more about the emerging Extensive Stage Small Cell Lung Cancer Pipeline Therapies @ Extensive Stage Small Cell Lung Cancer Clinical Trials Assessment

Scope of the Extensive Stage Small Cell Lung Cancer Pipeline Report

Coverage- Global
Extensive Stage Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Extensive Stage Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Extensive Stage Small Cell Lung Cancer Companies- Eli Lilly and Company, Genentech, Bristol-Myers Squibb, Henlix Biotech, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., BioNTech SE, Xencor, Inc., Haihe Biopharma Co., Ltd., aizhou HoudeAoke Biomedical Co., Ltd., Celgene, MedImmune, Xcovery Holding Company LLC, Lee’s Pharmaceutical Limited, Merck & Co, Astex Pharmaceuticals, and others.
Extensive Stages Small Cell Lung Cancer Pipeline Therapies- Ifinatamab Deruxtecan (I-DXd), Trilaciclib, Obatoclax, Carboplatin/etoposide, and others.

Dive deep into rich insights for new drugs for Extensive Stage Small Cell Lung Cancer Treatment, Visit @ Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Extensive Stage Small Cell Lung Cancer Executive Summary
Extensive Stage Small Cell Lung Cancer Overview
Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics
Extensive Stage Small Cell Lung Cancer Therapeutic Assessment
Late Stage Products (Phase III)
Tiragolumab: Genentech
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
LY 2510924: Eli Lilly and Company
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
SYHA 1807: CSPC ZhongQi Pharmaceutical Technology
Drug profiles in the detailed report…..
Inactive Products
Extensive Stage Small Cell Lung Cancer Companies
Extensive Stage Small Cell Lung Cancer Key Products
Extensive Stage Small Cell Lung Cancer Unmet Needs
Extensive Stage Small Cell Lung Cancer Market Drivers and Barriers
Extensive Stage Small Cell Lung Cancer Future Perspectives and Conclusion
Extensive Stage Small Cell Lung Cancer Analyst Views
Extensive Stage Small Cell Lung Cancer Key Companies
Appendix

For further information on the Extensive Stage Small Cell Lung Cancer Pipeline Therapeutics, reach out to Extensive Stage Small Cell Lung Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Extensive Stage Small Cell Lung Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)

DelveInsight’s, “Ewing Sarcoma Pipeline Insights 2024” report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Ewing Sarcoma Pipeline Report

DelveInsight’s Ewing Sarcoma pipeline report depicts a robust space with 25+ Ewing Sarcoma companies working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.
The leading Ewing Sarcoma Companies working in the market include Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
Promising Ewing Sarcoma Pipeline Therapies in the various stages of development includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
December 2023: St. Jude Children’s Research Hospital announced a study of Phase 1 & 2 clinical trials for Onivyde, Talazoparib and Temozolomide. The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm.
December 2023: Children’s Hospital of Philadelphia announced a study of Phase 1 clinical trials for Cabozantinib. The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.
December 2023: Fusion Pharmaceuticals Inc. announced a study of Phase 1 clinical trials for [225]-FPI-2059 and [111In]-FPI-2058. This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

Request a sample and discover the recent advances in Ewing Sarcoma Treatment Drugs @ Ewing Sarcoma Pipeline Outlook Report

The Ewing Sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ewing Sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ewing Sarcoma clinical trial landscape.

Ewing Sarcoma Overview

Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis.

Find out more about Ewing Sarcoma Treatment Landscape @ Drugs for Ewing Sarcoma Treatment

Ewing Sarcoma Emerging Drugs Profile

Vigil: Gradalis
ONCT216: Oncternal Therapeutics
SP-2577: Salarius Pharmaceuticals

Ewing Sarcoma Pipeline Therapeutics Assessment

There are approx. 25+ Ewing Sarcoma companies which are developing the Ewing Sarcoma therapies. The Ewing Sarcoma companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.

DelveInsight’s Ewing Sarcoma pipeline report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Ewing Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Ewing Sarcoma Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Learn more about the emerging Ewing Sarcoma Pipeline Therapies @ Ewing Sarcoma Clinical Trials Assessment

Scope of the Ewing Sarcoma Pipeline Report

Coverage- Global
Ewing Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Ewing Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
Ewing Sarcoma Pipeline Therapies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

Dive deep into rich insights for new drugs for Ewing Sarcoma treatment, Visit @ Ewing Sarcoma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Ewing Sarcoma Executive Summary
Ewing Sarcoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Ewing Sarcoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Vigil: Gradalis
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
ONCT216: Oncternal Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
SP-2577: Salarius Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CLR 131: Cellectar Biosciences
Drug profiles in the detailed report…..
Inactive Products
Ewing Sarcoma Companies
Ewing Sarcoma Key Products
Ewing Sarcoma Unmet Needs
Ewing Sarcoma Market Drivers and Barriers
Ewing Sarcoma Future Perspectives and Conclusion
Ewing Sarcoma Analyst Views
Ewing Sarcoma Key Companies
Appendix

For further information on the Ewing Sarcoma pipeline therapeutics, reach out to Ewing Sarcoma Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ewing Sarcoma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)

Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)

DelveInsight’s, “Diffuse Intrinsic Pontine Glioma Pipeline Insight 2024” report provides comprehensive insights about 25+ Diffuse Intrinsic Pontine Glioma companies and 25+ pipeline drugs in the Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the Diffuse Intrinsic Pontine Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Intrinsic Pontine Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Diffuse Intrinsic Pontine Glioma Pipeline Report

DelveInsight’s Diffuse Intrinsic Pontine Glioma pipeline report depicts a robust space with 25+ Diffuse Intrinsic Pontine Glioma companies working to develop 25+ pipeline therapies for Diffuse Intrinsic Pontine Glioma treatment.
The leading Diffuse Intrinsic Pontine Glioma Companies working in the market include Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation, and others.
Promising Diffuse Intrinsic Pontine Glioma Pipeline Therapies in the various stages of development includes BXQ-350, ONC201, PTC596, Radiotherapy, AloCELYVIR, Temozolomide, Bevacizumab, Irinotecan, and others.
December 2023: Luca Szalontay announced a study of Phase 1 clinical trials for Infusate with MTX110 and gadolinium. The purpose of this Phase I study is to find the maximum tolerated dose of MTX110 (a water-soluble Panobinostat nanoparticle formulation) and Gadolinium that can be given safely in children with newly diagnosed diffuse midline gliomas. All patients enrolled in the study will receive infusion of MTX110 and Gadolinium delivered with a pump directly into the tumor over 9-11 days.
December 2023: Sabine Mueller, MD, PhD announced a study of Phase 1 & 2 clinical trials for Nivolumab and K27M peptide. This study will assess the safety and immune activity of a synthetic peptide vaccine specific for the H3.3.K27M epitope given in combination with poly-ICLC and the H3.3.K27M epitope given in combination with poly-ICLC and the PD-1 inhibitor, nivolumab, in HLA-A2 (02:01)+ children with newly diagnosed DIPG or other midline gliomas that are positive for H3.3K27M.
December 2023: Y-mAbs Therapeutics announced a study of Phase 1 clinical trials for Radioactive iodine-labeled monoclonal antibody omburtamab. In this study, the researchers want to find out how safe 124I-omburtamab given by CED is at different dose levels. They will look to see what effects (both good and bad) it has on the patient. The dose of 124I-omburtamab will increase for each new group of patients. The procedure has already been safely performed with lower doses and infusion volumes in a number of patients here at MSKCC. The amount they get will depend on when they enter the study.

Request a sample and discover the recent advances in Diffuse Intrinsic Pontine Glioma Treatment Drugs @ Diffuse Intrinsic Pontine Glioma Pipeline Outlook Report

The Diffuse Intrinsic Pontine Glioma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Diffuse Intrinsic Pontine Glioma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Diffuse Intrinsic Pontine Glioma clinical trial landscape.

Diffuse Intrinsic Pontine Glioma Overview

Diffuse intrinsic pontine gliomas (DIPGs) are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain’s glial tissue — tissue made up of cells that help support and protect the brain’s neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body’s most vital functions such as breathing, blood pressure and heart rate.

Find out more about Diffuse Intrinsic Pontine Glioma Treatment Landscape @ Drugs for Diffuse Intrinsic Pontine Glioma Treatment

Diffuse Intrinsic Pontine Glioma Emerging Drugs Profile

MTX 110: Midatech
Paxalisib: Kazia Therapeutics

Diffuse Intrinsic Pontine Glioma Pipeline Therapeutics Assessment

There are approx. 25+ Diffuse Intrinsic Pontine Glioma companies that are developing the Diffuse Intrinsic Pontine Glioma therapies. The Diffuse Intrinsic Pontine Glioma companies that have their Diffuse Intrinsic Pontine Glioma drug candidates in the most advanced stage, i.e. phase I/II include, Midatech.

DelveInsight’s Diffuse Intrinsic Pontine Glioma pipeline report covers around 25+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates

Diffuse Intrinsic Pontine Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Diffuse Intrinsic Pontine Glioma Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Learn more about the emerging Diffuse Intrinsic Pontine Glioma Pipeline Therapies @ Diffuse Intrinsic Pontine Glioma Clinical Trials Assessment

Scope of the Diffuse Intrinsic Pontine Glioma Pipeline Report

Coverage- Global
Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Diffuse Intrinsic Pontine Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Diffuse Intrinsic Pontine Glioma Companies- Midatech, Kazia Therapeutics, Kintara Therapeutics, Oncotelic Therapeutics, Antisense Pharma, Y-mAbs Therapeutics, PTC Therapeutics, Celgene Corporation, and others.
Diffuse Intrinsic Pontine Glioma Pipeline Therapies- BXQ-350, ONC201, PTC596, Radiotherapy, AloCELYVIR, Temozolomide, Bevacizumab, Irinotecan, and others.

Dive deep into rich insights for new drugs for Diffuse Intrinsic Pontine Glioma treatment, Visit @ Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Diffuse Intrinsic Pontine Glioma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Diffuse Intrinsic Pontine Glioma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Drug name : Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase I/II)
MTX 110: Midatech
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Drug name : Company name
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name : Company name
Drug profiles in the detailed report…..
Inactive Products
Diffuse Intrinsic Pontine Glioma Key Companies
Diffuse Intrinsic Pontine Glioma Key Products
Diffuse Intrinsic Pontine Glioma Unmet Needs
Diffuse Intrinsic Pontine Glioma Market Drivers and Barriers
Diffuse Intrinsic Pontine Glioma Future Perspectives and Conclusion
Diffuse Intrinsic Pontine Glioma Analyst Views
Diffuse Intrinsic Pontine Glioma Key Companies
Appendix

For further information on the Diffuse Intrinsic Pontine Glioma pipeline therapeutics, reach out to Diffuse Intrinsic Pontine Glioma Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)

Bestselling Author and Speaker Michael D. Wynn Honored with the President’s Lifetime Achievement Award

“Coach Win” recognized for reaching thousands of individuals to alleviate financial burdens and extend crucial support for those in need.

New York – Bestselling author, speaker, and financial literacy coach Michael D. Wynn has been awarded the President’s Lifetime Achievement Award for his outstanding service to the community.

“On behalf of the American people, I extend my heartfelt appreciation to you for your volunteer leadership, and I encourage you to continue to answer the call to serve,” wrote President Joe Biden in a letter to Wynn. “The country is counting on you,” the President stated.

“I am so honored to be among the few recipients of the esteemed President’s Lifetime Achievement Award,” said Wynn. “My commitment to aiding low-income families through income tax preparation, conducting financial literacy outreach programs, facilitating Money Smart financial literacy training, and publishing articles on financial literacy and identity fraud protection over several years has been immensely fulfilling.”

The President’s Lifetime Achievement Award honors individuals who make a positive impact on their community and complete more than 4,000 hours of volunteer service in their lifetime.

With more than 35 years as a financial audit specialist, fiscal monitor and business compliance specialist, Wynn teaches, consults, and trains both individuals and business teams to pursue development, growth, substantial profits, and stability through his unique “Habit Matrix.”

“Financial literacy is a subject we can all use more of since it’s not taught enough in schools,” say Dr. ZaLonya Allen, President and CEO of National Entrepreneurs Association. “Michael Wynn’s book does a great job of breaking down how to manage your finances in a way that anyone should be able to understand.”

“Mike Wynn has always been an energetic, impressive individual that has been involved in some powerful projects in the inner city with me,” says Lois Gibbons, Former Financial Literacy Director, Account Aid Society. “His incredible background and wealth of knowledge helped individuals many times throughout the metropolitan area, for which I am most grateful.”

Wynn will be presented with the award as he speaks at The Leadership Experience Tour (LET) dinner on March 23, 2024, at the Michigan State University Convention Center in Troy, Michigan.

Michael Wynn connects with leaders, business teams, and organizations that thrive on a winning strategy through repetition and growth development. As a habit success strategist, financial expert, author, and speaker he is inspired to make a difference. He is the author of two bestselling books: Habits Don’t Lie: 7 Habits to Overcome Obstacles To Win and The Habit Effect: Your Life, Your Money. Committed to raising financial literacy awareness, he holds certifications as an authenticity coach, financial literacy trainer and fraud examiner.

To learn more about coaching, programs, and speaking opportunities featuring Michael Wynn, visit https://MichaelWynn.com.

Media Contact
Company Name: Vizabol Media
Contact Person: Ralph Brogden
Email: Send Email
Phone: 347-827-1562
Country: United States
Website: https://vizabol.com

New Book from Publisher and Book Marketing Strategist Melanie Herschorn Offers Simple Success Roadmap for First-Time Authors

While it is easier than ever to write and self-publish a book, Herschorn says the success of a book is determined not by superior ideas, but by superior marketing strategies.

New York – For thought leadership and authority positioning, experts agree that nothing compares with writing a book. And, with the ease of self-publishing and on-demand platforms such as Amazon or IngramSpark, almost anyone can write and publish a book.

That ease of access has created something of a crisis for book sales, however. According to Steven Piersanti, Senior Editor at Berrett-Koehler Publishers, “Average book sales are shockingly small – and falling fast.” In addition to an over-saturated book market and a surplus of books available on every topic, Piersanti says that “most book marketing today is done by authors, not by publishers.” And, since most book authors are not book marketers, this means that 90% of self-published authors will never sell more than 100 copies of their book.

Melanie Herschorn, publisher and book marketing strategist at VIP Book Marketing and Publishing, is on a mission to turn that around. “With the recent shifts in the publishing industry that have lowered the barrier to entry, new authors can easily publish their books to Amazon and other platforms,” Herschorn says. “However, publishing companies rarely provide comprehensive marketing guidance, leaving thousands of new authors with boxes of books that collect dust and do not sell.”

Herschorn, author of Make a Big Impact with Your Book: Author Marketing Strategies for Long-Term Success, understands this struggle. She works with non-fiction authors and children’s book authors, offering expert insights for building awareness and credibility with targeted marketing techniques, innovative ways to reach the ideal audience, and proven strategies to increase book sales. Herschorn’s company, VIP Book Marketing and Publishing, provides nonfiction and children’s book authors with the step-by-step guidance they need to sell more books, create brand visibility, and truly make an impact in the world.

Herschorn’s expertise as a celebrity publicist, award-winning journalist, and entrepreneur uniquely positions her to guide authors on their journey to thought leadership and success. “Both the publishing industry and the broader media landscape have become so fragmented that just the idea of trying to navigate them can totally paralyze a new author,” says Scott Detrow, weekend host of All Things Considered and co-host of the Consider This podcast at NPR. “In Make A Big Impact, Melanie Herschorn has written an accessible, confidence-boosting step-by-step approach that will help authors get their books into people’s hands, and their ideas into reader’s minds.”

“My first book was the catalyst for the thriving community and business I have today, so I know firsthand how vital the marketing component of a book launch is!” says Lindsey Schwartz, author and founder, Powerhouse Women. “Melanie Herschorn’s new book is exactly what new authors need to ensure that their books have longevity and make a real difference.”

“I want to help new authors step into their rightful spotlight with their book,” Herschorn says. “I am on a mission to support and empower professionals, consultants, business owners and speakers to truly shine a light on what makes their story unique, special, and impactful.”

Melanie Herschorn is a publisher and book marketing strategist with VIP Book Marketing and Publishing. With a comprehensive background as a celebrity publicist, Edward R. Murrow and AP award-winning journalist, clothing designer, and entrepreneur, Herschorn supports authors in stepping into thought leadership and making a difference with their books. She is a Certified Book Publicity Professional with the Nonfiction Authors Association and holds a master’s degree in Broadcast Journalism from the University of Southern California.

To learn more about author marketing services from VIP Book Marketing and Publishing, or to purchase Make A Big Impact with Your Book: Author Marketing Strategies for Long-Term Success, visit https://vipbookmarketing.com.

Media Contact
Company Name: Vizabol Media
Contact Person: Ralph Brogden
Email: Send Email
Phone: 347-827-1562
Country: United States
Website: https://vizabol.com

Renal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

DelveInsight’s, “Renal Cancer Pipeline Insight 2024” report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Renal Cancer Pipeline Report

DelveInsight’s Renal Cancer pipeline report depicts a robust space with 75+ Renal Cancer companies working to develop 80+ pipeline therapies for Renal Cancer treatment.
The leading Renal Cancer Companies working in the market includes Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
Promising Renal Cancer Pipeline Therapies in the various stages of development includes Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.
December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Nivolumab, Cabozantinib, Sunitinib and Ipilimumab. The purpose of this study is to determine whether Nivolumab Combined with Cabozantinib is safe and effective compared to Sunitinib in previously untreated advanced or metastatic renal cell carcinoma.
December 2023: Pfizer announced a study of Phase 3 clinical trials for Avelumab (MSB0010718C), Axitinib (AG-013736) and Sunitinib. This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma.
December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

Request a sample and discover the recent advances in Renal Cancer Treatment Drugs @ Renal Cancer Pipeline Outlook Report

The Renal Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Renal Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Renal Cancer clinical trial landscape.

Renal Cancer Overview

Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer. Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. In early stages Renal carcinoma is symptom free but as the diseases progresses the symptoms may include: lump in the abdomen, fatigue, and unexplained weight loss, blood in the urine, loss of appetite, vision problem, and excessive hair growth. Renal cell carcinoma is the most common type of adult kidney cancer. It is responsible for approximately 85% of kidney neoplasms. Renal cell carcinoma may be clinically asymptomatic for the majority of its course.

Find out more about Renal Cancer Treatment Landscape @ Drugs for Renal Cancer Treatment

Renal Cancer Emerging Drugs Profile

Atezolizumab : Genentech
Olaparib: AstraZeneca
MK-4830 : Merck & Co., Inc
ALLO-316 : Allogene Therapeutics

Renal Cancer Pipeline Therapeutics Assessment

There are approx. 75+ Renal Cancer companies which are developing the Renal Cancer therapies. The Renal Cancer companies which have their Renal Cancer drug candidates in the most advanced stage, i.e. phase III include, Genentech.

Delve Insight’s Renal Cancer pipeline report covers around 80+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Renal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
intravenous
Subcutaneous
Topical

Renal Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Renal Cancer Pipeline Therapies @ Renal Cancer Clinical Trials Assessment

Scope of the Renal Cancer Pipeline Report

Coverage- Global
Renal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Renal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Renal Cancer Companies- Genentech, AstraZeneca, Allogene Therapeutics, Merck & Co. Inc., X4 Pharmaceuticals, Argos Therapeutics, Pfizer, Eisai Inc., Merck Sharp & Dohme LLC, Bristol-Myers Squibb, AVEO Pharmaceuticals Inc., Mabwell (Shanghai) Bioscience Co., Ltd., Beijing Scitech-Mq Pharmaceuticals Limited, Qilu Pharmaceutical Co., Ltd., Jiangsu Hansoh Pharmaceutical Co., Ltd., and others.
Renal Cancer Pipeline Therapies- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab, Axitinib, MK-3475, Bevacizumab, Interferon alpha-2a, CP-461, and others.

Dive deep into rich insights for new drugs for Renal Cancer treatment, Visit @ Renal Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Renal Cancer Executive Summary
Renal Cancer: Overview
Renal Cancer Pipeline Therapeutics
Renal Cancer Therapeutic Assessment
Late Stage Products (Phase III)
Comparative Analysis
Atezolizumab: Genentech
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Olaparib: AstraZeneca
Early Stage Products (Phase I)
Allogene Therapeutics: ALLO-316
Inactive Products
Renal Cancer Companies
Renal Cancer Products
Renal Cancer Unmet Needs
Renal Cancer Market Drivers and Barriers
Renal Cancer Future Perspectives and Conclusion
Renal Cancer Analyst Views
Appendix

For further information on the Renal Cancer pipeline therapeutics, reach out to Renal Cancer Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Renal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

Parkinson’s Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

DelveInsight’s, “Parkinson’s Disease Pipeline Insight 2024” report provides comprehensive insights about 140+ Parkinson’s Disease companies and 150+ pipeline drugs in Parkinson’s Disease pipeline landscape. It covers the Parkinson’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Parkinson’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Parkinson’s Disease Pipeline Report

DelveInsight’s Parkinson’s Disease pipeline report depicts a robust space with 140+ active players working to develop 150+ pipeline therapies for Parkinson’s Disease treatment.
The leading Parkinson’s Disease companies working in the market include Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
Promising Parkinson’s Disease Pipeline Therapies in the various stages of development include BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.
December 2023: AC Immune SA announced a study of Phase 2 clinical trials for ACI-7104.056 at Dose A. The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 vaccination in patients with early stages of Parkinson’s disease. This is a prospective, multicenter, placebo-controlled, double-blind, randomized study with adaptive features, comprising a screening period of up to 8 weeks, a 74-week double-blind treatment period, and a 26-week post-treatment follow-up period.
December 2023: Prevail Therapeutics announced a study of phase 1 & 2 clinical trials for Methylprednisolone and Sirolimus. A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients With Parkinson’s Disease With at Least One GBA1 Mutation (PROPEL).
July 2023: Hoffmann-La Roche announced a study of phase 2 clinical trials for Prasinezumab. This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson’s Disease (PD) who are on stable symptomatic PD medication.
March 2023: Neurocrine Biosciences announced a study of phase 2 clinical trials for VY-AADC02. The objectives of this study are to assess the efficacy, safety and tolerability of VY-AADC02 in Patients with Parkinson’s Disease with Motor Fluctuations.

Request a sample and discover the recent advances in Parkinson’s Disease Treatment Drugs @ Parkinson’s Disease Pipeline Outlook Report

In the Parkinson’s Disease pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson’s disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Parkinson’s Disease Overview

Parkinson’s disease is a progressive disorder that is caused by degeneration of nerve cells in the part of the brain called the substantia nigra, which controls movement. These nerve cells die or become impaired, losing the ability to produce an important chemical called dopamine.

Find out more about Parkinson’s Disease Treatment Landscape @ Drugs for Parkinson’s Disease Treatment

Parkinson’s Disease Emerging Drugs Profile

Tavapadon: Cerevel Therapeutics
IkT-148009: Inhibikase Therapeutics
NLY01: Neuraly
PT320: Peptron

Parkinson’s Disease Pipeline Therapeutics Assessment

There are approx. 140+ key Parkinson’s Disease companies which are developing the Parkinson’s Disease therapies. The Parkinson’s Disease companies which have their Parkinson’s disease drug candidates in the most advanced stage, i.e. phase III include, Cerevel Therapeutics.

DelveInsight’s Parkinson’s Disease pipeline report covers around 150+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Parkinson’s disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Parkinson’s Disease Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Learn more about the emerging Parkinson’s Disease Pipeline Therapies @ Parkinson’s Disease Clinical Trials Assessment

Scope of the Parkinson’s Disease Pipeline Report

Coverage- Global
Parkinson’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Parkinson’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Parkinson’s Disease Companies- Cerevel Therapeutics, Inhibikase Therapeutics, Neuraly, Peptron, Biogen, Roche, Brain Neurotherapy Bio, Inc., Modag, Annovis Bio Inc., BioVie Inc., United Neuroscience Ltd., Luye Pharma Group, AbbVie, UCB Biopharma SRL, InnoMedica Schweiz AG, Integrative Research Laboratories AB, H. Lundbeck A/S, Shanghai WD Pharmaceutical Co., Ltd., Cerevance Beta, Inc., Nobilis Therapeutics Inc., BlueRock Therapeutics, Taiwan Mitochondrion Applied Technology Co., Ltd., NeuroDerm Ltd., Pharma Two B, Serina Therapeutics, Sun Pharma Advanced Research Company Limited, CuraSen Therapeutics, Inc., Takeda, Xoc Pharmaceuticals, Sumitomo Pharma Co., Ltd., XWPharma, Athira Pharma, Aptinyx, VistaGen Therapeutics, Inc., 1ST Biotherapeutics, Inc., Novo Nordisk A/S, AstraZeneca, MedImmune, Anavex Life Sciences Corp., Living Cell Technologies, Intra-Cellular Therapies, Inc., Alkahest, Inc., Kissei Pharmaceutical Co., Ltd., and others.
Parkinson’s Disease Pipeline Therapies- BIIB122, LY03003, Istradefylline 20 mg or 40 mg, Istradefylline 40 mg, LY3884961, Methylprednisolone, Sirolimus, KM-819, and others.

Dive deep into rich insights for new drugs for Parkinson’s Disease treatment, Visit @ Parkinson’s Disease Market Drivers and Barriers, and Future Perspective

Table of Content

Introduction
Executive Summary
Parkinson’s Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Parkinson’s Disease – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tavapadon: Cerevel Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Prasinezumab : Roche
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MEDI1341: AstraZeneca
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Neural microtissues: Treefrog Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Parkinson’s Disease Companies
Parkinson’s Disease Products
Parkinson’s Disease Unmet Needs
Parkinson’s Disease Market Drivers and Barriers
Parkinson’s Disease Future Perspectives and Conclusion
Parkinson’s Disease Analyst Views
Parkinson’s Disease Companies
Appendix

For further information on the Parkinson’s Disease pipeline therapeutics, reach out to Parkinson’s Disease Unmet Needs and Analyst Views

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Parkinson\’s Disease Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2024 (Updated)

PSMA-Targeted Therapy Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – Novartis

“DelveInsight Business Research LLP”

The PSMA-Targeted Therapy market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is likely to necessitate extensive clinical trials to establish both safety and efficacy.

DelveInsight’s PSMA-Targeted Therapy Market Insights report offers a thorough understanding of prevailing treatment protocols, emerging therapies, individual therapy market shares, and the projected market size for PSMA-Targeted Therapy from 2019 to 2032. The market analysis is segmented across the 7MM, encompassing the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

Key Takeaways from the PSMA-Targeted Therapy Market Report

According to DelveInsight’s analysis, the PSMA-Targeted Therapy market is expected to exhibit substantial growth, with a significant Compound Annual Growth Rate (CAGR) projected by 2032.
Some of the prominent companies in the PSMA-Targeted Therapy segment, such as Novartis, and others are actively pioneering the development of innovative PSMA-Targeted Therapy, with potential market availability anticipated in the forthcoming years.
Some notable marketed and emerging PSMA-Targeted Therapies in the market include Pluvicto, alongside others.

PSMA-Targeted Therapy Overview

PSMA, or Prostate-Specific Membrane Antigen, is a cell surface protein overexpressed in prostate cancer cells and certain other malignancies, including bladder cancer and some types of breast and pancreatic cancers. PSMA-targeted therapy involves the use of radiolabeled ligands or antibodies that specifically bind to PSMA, delivering cytotoxic agents or radiation directly to cancer cells while sparing healthy tissues.

Mechanism of Action of PSMA-Targeted Therapy

PSMA-targeted therapy exploits the overexpression of PSMA on cancer cells to deliver therapeutic agents selectively. Radiolabeled ligands or antibodies targeting PSMA bind to PSMA-expressing cancer cells with high affinity. Upon binding, the therapeutic payload, typically a radioactive isotope or cytotoxic drug, is internalized into the cancer cell, where it exerts its cytotoxic effects. Radiation emitted by the radioactive isotope induces DNA damage and cell death, while cytotoxic drugs disrupt cellular processes crucial for cancer cell survival.

Applications in Cancer Treatment:

Prostate Cancer: PSMA-targeted therapy has shown remarkable efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC), a stage of prostate cancer that has become resistant to hormone therapy. Radiolabeled PSMA ligands such as Lutetium-177 PSMA-617 have demonstrated significant tumor regression and prolonged survival in patients with mCRPC.
Other PSMA-Expressing Cancers: Beyond prostate cancer, PSMA-targeted therapy holds promise for the treatment of other cancers expressing PSMA, including bladder cancer, breast cancer, and pancreatic cancer. Clinical trials are underway to evaluate the efficacy of PSMA-targeted therapy in these malignancies, offering potential new treatment options for patients with limited therapeutic alternatives.
Precision Medicine: PSMA-targeted therapy exemplifies the principles of precision medicine, wherein treatment strategies are tailored to the molecular characteristics of individual tumors. By targeting PSMA, which is selectively expressed on cancer cells, PSMA-targeted therapy minimizes off-target effects and maximizes therapeutic efficacy, leading to improved patient outcomes and quality of life.

PSMA-Targeted Therapy Market Outlook

The future market outlook for PSMA-targeted therapy is promising, driven by the increasing incidence of prostate cancer and the expanding applications of PSMA-targeted agents across various cancer types. With ongoing research and development efforts focused on optimizing PSMA-targeted agents, including the development of novel radiolabeled ligands and antibody-drug conjugates, the therapeutic landscape for PSMA-targeted therapy is poised to evolve rapidly. Furthermore, advancements in imaging technologies, such as PSMA-targeted PET imaging, are expected to enhance patient selection and monitoring of treatment response, further driving the adoption of PSMA-targeted therapy in clinical practice.

Key PSMA-Targeted Therapy Therapies and Companies

Pluvicto – Novartis

And Many Others

Get a Comprehensive Evaluation of Ongoing Clinical, Commercial, and Regulatory Advancements in the PSMA-Targeted Therapy Sector:

https://www.delveinsight.com/sample-request/psma-targeted-therapy-market-forecast

PSMA-Targeted Therapy Market Dynamics

PSMA-targeted therapy represents a paradigm shift in cancer treatment, offering a highly targeted approach to delivering therapeutic agents directly to cancer cells while sparing healthy tissues. With its proven efficacy in prostate cancer and promising results in other PSMA-expressing malignancies, PSMA-targeted therapy holds immense potential for improving treatment outcomes and quality of life for cancer patients.

The landscape of the PSMA-Targeted Therapy market is poised for transformation in the foreseeable future. With a burgeoning drug pipeline, PSMA-Targeted Therapy presents a promising opportunity for major corporations to bolster their market presence significantly. This is particularly evident in the emergence of diverse and robust pipelines, which offer ample potential for growth and market expansion.

Moreover, ongoing research is exploring numerous potential therapies aimed at addressing PSMA-Targeted Therapy, underscoring the anticipation of substantial influence on the market throughout the projected period. Additionally, the impending debut of novel therapies boasting enhanced efficacy, coupled with advancements in diagnosis rates, is poised to fuel the expansion of the PSMA-Targeted Therapy market across the 7MM (Seven Major Markets).

Additionally, the trajectory of growth in the PSMA-Targeted Therapy market could encounter impediments such as setbacks and discontinuation of promising therapies, challenges related to affordability, market access, and reimbursement hurdles, as well as a scarcity of healthcare professionals with specialized expertise in this domain.

Scope of the PSMA-Targeted Therapy Market Report

The report includes key event summaries, an overview of the target patient demographics, epidemiological projections, market forecasts, insights into patient pathways, and diverse biomarker testing rates.
Furthermore, the report provides comprehensive coverage of current and emerging therapies, including insights on the addressable patient population for PSMA-Targeted Therapy.
The report includes an in-depth examination of the PSMA-Targeted Therapy market, covering historical and projected market size, therapy market shares, detailed assumptions, and the rationale behind our analytical approach.
The report offers a strategic advantage in business planning by leveraging SWOT analysis, expert insights, and input from key opinion leaders (KOLs) to understand market trends and treatment preferences, thereby influencing and propelling the growth of PSMA-Targeted Therapy.

Explore More About PSMA-Targeted Therapy in Development and Key Competitors in the Domain:

https://www.delveinsight.com/sample-request/psma-targeted-therapy-market-forecast

Table of Contents

1. PSMA-Targeted Therapy Market Key Insights

2. PSMA-Targeted Therapy Market Report Introduction

3. PSMA-Targeted Therapy Market Overview at a Glance

4. PSMA-Targeted Therapy Market Executive Summary

5. Disease Background and Overview

6. PSMA-Targeted Therapy Treatment and Management

7. Epidemiology and Patient Population

8. Patient Journey

9. Marketed PSMA-Targeted Therapy

10. Emerging PSMA-Targeted Therapy

11. PSMA-Targeted Therapy Market Analysis (Across 7MM)

12. PSMA-Targeted Therapy Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

To Gain Deeper Insights into the Scope of the Reports and its Key Coverage Areas, Download the Sample PDF:

https://www.delveinsight.com/sample-request/psma-targeted-therapy-market-forecast

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Reports By DelveInsight

Gene and Cell Therapies Targeting CNS Disorders Market

“Gene and Cell Therapies Targeting CNS Disorders Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gene and Cell Therapies Targeting CNS Disorders market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Gene and Cell Therapies Targeting CNS Disorders market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: PSMA-Targeted Therapy Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – Novartis

Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – Eli Lilly

“DelveInsight Business Research LLP”

The Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist market size is anticipated to grow in the upcoming years, largely driven by heightened R&D endeavors across the 7MM. Furthermore, the competitive landscape remains relatively sparse, indicating that the regulatory approval process is likely to necessitate extensive clinical trials to establish both safety and efficacy.

DelveInsight’s Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Insights report offers a thorough understanding of prevailing treatment protocols, emerging therapies, individual therapy market shares, and the projected market size for Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist from 2019 to 2032. The market analysis is segmented across the 7MM, encompassing the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan.

Key Takeaways from the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Report

According to DelveInsight’s analysis, the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist market is expected to exhibit substantial growth, with a significant Compound Annual Growth Rate (CAGR) projected by 2032.
Some of the prominent companies in the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist segment such as Eli Lilly, and others are actively pioneering the development of innovative Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist, with potential market availability anticipated in the forthcoming years.
Some notable marketed and emerging Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist in the market include Mounjaro (GIP+GLP-1), Retatrutide (GIP/GLP-1/Glucagon Receptor Agonist), alongside others.

Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Overview

Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted by enteroendocrine K cells in the gastrointestinal tract in response to nutrient ingestion, particularly glucose and fatty acids. GIP acts as an incretin hormone alongside glucagon-like peptide-1 (GLP-1), stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner. GIP agonists are synthetic analogs or mimetics of endogenous GIP, designed to enhance GIP receptor activity and improve glucose homeostasis.

Mechanism of Action of Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist

GIP agonists exert their effects primarily through interaction with GIP receptors, which are expressed on pancreatic beta cells, adipocytes, and other tissues involved in glucose metabolism. Upon binding to GIP receptors, GIP agonists stimulate insulin secretion from pancreatic beta cells in response to elevated blood glucose levels. Additionally, GIP agonists promote the proliferation and survival of pancreatic beta cells, enhancing their capacity for insulin production and secretion. Furthermore, GIP agonists exert incretin effects on adipocytes, promoting lipid metabolism and contributing to overall metabolic homeostasis.

Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Applications in Diabetes Management

Type 2 Diabetes Treatment: GIP agonists offer a novel therapeutic approach for the management of type 2 diabetes mellitus (T2DM). By enhancing insulin secretion and promoting beta cell function, GIP agonists help improve glycemic control and reduce hyperglycemia in patients with T2DM. GIP agonists can be used as monotherapy or in combination with other antidiabetic agents, such as metformin or GLP-1 receptor agonists, to achieve optimal glycemic outcomes.
Obesity Management: GIP agonists exhibit beneficial effects on body weight and adiposity by promoting lipid metabolism and energy expenditure. As obesity is a significant risk factor for the development of insulin resistance and T2DM, GIP agonists hold potential for the management of obesity-related metabolic disorders.
Cardiovascular Protection: Emerging evidence suggests that GIP agonists may confer cardiovascular benefits beyond glycemic control. GIP receptor activation has been associated with improvements in endothelial function, vascular inflammation, and atherosclerosis, indicating a potential role for GIP agonists in cardiovascular risk reduction among patients with diabetes.

Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Outlook

The future market outlook for GIP agonists is promising, driven by the increasing prevalence of diabetes and obesity worldwide, coupled with the growing demand for innovative therapeutic options. As research continues to elucidate the therapeutic potential of GIP agonists and clinical development progresses, the market for GIP agonists is expected to expand significantly. Furthermore, advancements in drug delivery technologies, such as long-acting formulations and oral administration options, may further enhance the accessibility and usability of GIP agonists in clinical practice.

Key Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Therapies and Companies

Mounjaro (GIP+GLP-1) – Eli Lilly
Retatrutide (GIP/GLP-1/Glucagon Receptor Agonist) – Eli Lilly

And Many Others

Get a Comprehensive Evaluation of Ongoing Clinical, Commercial, and Regulatory Advancements in the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Sector:

https://www.delveinsight.com/sample-request/glucose-dependent-insulinotropic-polypeptide-gip-agonist-market-forecast

Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Dynamics

Glucose-dependent insulinotropic polypeptide (GIP) agonists represent a novel and promising class of therapeutics for the management of diabetes mellitus and related metabolic disorders. By leveraging the physiological role of GIP in glucose homeostasis and metabolic regulation, GIP agonists offer a targeted approach to improving glycemic control, reducing body weight, and potentially mitigating cardiovascular risk.

The landscape of the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist market is poised for transformation in the foreseeable future. With a burgeoning drug pipeline, Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist presents a promising opportunity for major corporations to bolster their market presence significantly. This is particularly evident in the emergence of diverse and robust pipelines, which offer ample potential for growth and market expansion.

Moreover, ongoing research is exploring numerous potential therapies aimed at addressing Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist, underscoring the anticipation of substantial influence on the market throughout the projected period. Additionally, the impending debut of novel therapies boasting enhanced efficacy, coupled with advancements in diagnosis rates, is poised to fuel the expansion of the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist market across the 7MM (Seven Major Markets).

Additionally, the trajectory of growth in the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist market could encounter impediments such as setbacks and discontinuation of promising therapies, challenges related to affordability, market access, and reimbursement hurdles, as well as a scarcity of healthcare professionals with specialized expertise in this domain.

Scope of the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Report

The report includes key event summaries, an overview of the target patient demographics, epidemiological projections, market forecasts, insights into patient pathways, and diverse biomarker testing rates.
Furthermore, the report provides comprehensive coverage of current and emerging therapies, including insights on the addressable patient population for Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist.
The report includes an in-depth examination of the Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist market, covering historical and projected market size, therapy market shares, detailed assumptions, and the rationale behind our analytical approach.
The report offers a strategic advantage in business planning by leveraging SWOT analysis, expert insights, and input from key opinion leaders (KOLs) to understand market trends and treatment preferences, thereby influencing and propelling the growth of Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist.

Explore More About Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist in Development and Key Competitors in the Domain:

https://www.delveinsight.com/sample-request/glucose-dependent-insulinotropic-polypeptide-gip-agonist-market-forecast

Table of Contents

1. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Key Insights

2. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Report Introduction

3. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Overview at a Glance

4. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Executive Summary

5. Disease Background and Overview

6. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Treatment and Management

7. Epidemiology and Patient Population

8. Patient Journey

9. Marketed Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist

10. Emerging Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist

11. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Analysis (Across 7MM)

12. Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

To Gain Deeper Insights into the Scope of the Reports and its Key Coverage Areas, Download the Sample PDF:

https://www.delveinsight.com/sample-request/glucose-dependent-insulinotropic-polypeptide-gip-agonist-market-forecast

About DelveInsight

Other Trending Reports By DelveInsight

Glioma Market

“Glioma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Glioma market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Glioma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glucose-dependent Insulinotropic Polypeptide (GIP) Agonist Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – Eli Lilly